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UK prescribing practices as proxy markers of unmet need
in allergic rhinitis: a retrospective observational study
David B Price1,2,3, Glenis Scadding4, Claus Bachert5, Hesham Saleh6, Shuaib Nasser7, Victoria Carter8, Julie von Ziegenweidt2,
Alice MS Durieux2 and Dermot Ryan9
Little data on UK prescribing patterns and treatment effectiveness for allergic rhinitis (AR) are available. We quantiﬁed unmet
pharmacologic needs in AR by assessing AR treatment effectiveness based on the prescribing behaviour of UK general practitioners
(GP) during two consecutive pollen seasons (2009 and 2010). We conducted a retrospective observational study with the data from
the Optimum Patient Care Research Database. We assessed diagnoses and prescription data for patients with a recorded diagnosis
of rhinitis who took rhinitis medication during the study period. We assessed the data from 25,069 patients in 2009 and 22,381
patients in 2010. Monotherapy was the initial prescription of the season for 67% of patients with seasonal AR (SAR) and 77%
of patients with nonseasonal upper airways disease (NSUAD), for both years. Initial oral antihistamine (OAH) or intranasal
corticosteroid (INS) monotherapy proved insufﬁcient for 420% of SAR and 437% of NSUAD patients. Multiple therapy was the
initial prescription for 33% of SAR and 23% of NSUAD in both years, rising to 45% and 450% by season end, respectively. For
NSUAD, dual-therapy prescriptions doubled and triple-therapy prescriptions almost tripled during both seasons. Many patients
revisited their GP regardless of initial prescription. Initial OAH or INS monotherapy provides insufﬁcient symptom control for many
AR patients. GPs often prescribe multiple therapies at the start of the season, with co-prescription becoming more common as the
season progresses. However, patients prescribed multiple therapies frequently revisit their GP, presumably to adjust treatment.
These data suggest the need for more effective AR treatment and management strategies.
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INTRODUCTION
As a disease, allergic rhinitis (AR) is one of the most under-
estimated diseases, in terms of its impact, severity, treatment and
cost. More high-proﬁle diseases, such as asthma, diabetes and
heart disease, have been well quantiﬁed in terms of their impact,
but not AR. AR affects ~ 600 million individuals in Europe1 and
~ 90 million in the United States.2 It has a substantial negative
impact on patients’ lives if uncontrolled,1,3,4 with high associated
costs, particularly indirect ones,5,6 which could be reduced by
effective symptom control.
From the patient perspective, having symptomatic AR means
living with any or all of the symptoms of nasal congestion,
headache, postnasal drip, repeated sneezing, runny nose and
other symptoms on a near-daily basis.7–9 Ocular symptoms are
common, difﬁcult to control and have the greatest negative
impact on patients’ quality of life.10,11 AR symptoms impair
patients’ function in day-to-day life,4,12,13 and cause sleep
disturbance,14 fatigue, absenteeism and productivity loss at work
and school (presenteeism).3,15,16 For those with co-morbid asthma,
the presence of signiﬁcant AR also predicts poor asthma control.17
From a physician's perspective, AR is becoming more
challenging to diagnose and treat. The majority of AR patients
attending clinic have moderate/severe disease,11,18 with most of
them ﬁrst visiting their doctor when their AR symptoms become
‘intolerable’.19 Data on sensitisation are often limited and
conﬂicting, and patients are commonly poly-sensitised,4,20,21
making allergen avoidance problematic. Many also suffer from
both allergic and non-allergic disease,22 and up to one-ﬁfth of the
patients are resistant or unresponsive to guideline-directed
therapy.23 Furthermore, 10–11% of the UK and European
population suffers from chronic rhinosinusitis, which may
present overlapping symptoms.24,25 Finally, many physicians
underestimate AR severity and consequently fail to issue adequate
treatment,26,27 a situation that appears to have changed little in a
decade.28
The Allergic Rhinitis and its Impact on Asthma (ARIA) Guideline
proposes a stepwise approach to AR management depending on
the severity and duration of symptoms,1,29 with the ultimate aim
of symptom control. Intranasal steroids (INS) are recommended as
ﬁrst-line treatment for moderate/severe AR, both intermittent and
persistent, and are currently considered the most effective
medication class.1,29,30 ARIA currently states that there are
insufﬁcient data available to make a recommendation concerning
the combined use of oral antihistamines (OAH) and INS,1 with
most of the published literature showing no beneﬁts gained by
adding other AR treatments to INS therapy.31,32
The aim of this retrospective study was to quantify the unmet
medical need in seasonal and perennial AR, speciﬁcally from the
UK payer perspective. This unmet need was quantiﬁed using data
on AR prescription to assess AR therapy failure, shift towards
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multiple therapy prescriptions and multiple General Practitioner
(GP) consultations, all of which are proxy measures of symptom
control, during two consecutive pollen seasons. To our
knowledge, this is the ﬁrst study to provide quantitative data on
these prescribing patterns in the UK.
RESULTS
Baseline characteristics
GP prescription data from 25,069 patients were assessed in
2009 and from 22,381 patients in 2010 (Table 1). The average age
was about 30 years for seasonal AR (SAR) and about 47 years
for nonseasonal upper airways disease (NSUAD) patients.
Approximately one-third of SAR patients and over half of NSUAD
patients had co-morbid asthma. About one-third of patients in
both groups had an eczema diagnosis; co-morbid diagnoses of
urticaria and nasal polyps were rare (o10% and o5% of patients,
respectively). Most of the patients were non-smokers (Table 1).
Initial recorded prescription of the season
Most patients commenced the season on a single AR therapy
(SAR: 67%; NSUAD: 77%), with similar ﬁgures noted in 2009 and
2010 (Table 2). OAH monotherapy was the most common initial
prescription, prescribed to over half of the patients, regardless
of phenotype. INS, the second most commonly prescribed
monotherapy, was more frequently prescribed to NSUAD patients
(2009/2010 SAR: 8.0/7.2%; NSUAD: 15.3/16.6%) as initial therapy.
However, a signiﬁcant proportion (particularly in SAR patients)
commenced the season on multiple therapy, with a similar
incidence of co-prescribing behaviour in 2009 (SAR: 33.0%;
NSUAD: 23.0%) and 2010 (SAR: 33.5%; NSUAD: 23.1%). OAH+INS
was the most common multiple therapy regimen prescribed at the
beginning of the season for both groups (2009/2010 SAR:
11.7/11.6%; NSUAD 10.1/10.0%). Eye drops were more commonly
co-prescribed with OAH for SAR (2009/2010: 8.9/9.1%) than for
NSUAD patients (2009/2010: 3.6/3.7%). Similarly, the triple-therapy
regimen of OAH+INS+eye drops was prescribed more frequently
at the start of the season to SAR (2009/2010: 8.9/9.5%) than to
NSUAD patients (2009/2010: 3.0/2.9%; Table 2).
Treatment outcomes for AR patients who commenced the season
on monotherapy
For SAR patients who started the 2009 season on OAH
monotherapy, 8.8% of them changed OAH (within the same
class), 15.7% added on a new therapy and 4.1% changed OAH and
added on a new therapy (Figure 1a; Supplementary Table S1).
A similar pattern was observed for the 2010 season. Treatment
change following initial OAH prescription was more apparent
in the NSUAD patients with a change of OAH noted in 12.6%
of patients, therapy add-on in 34.5% and both OAH change
and add-on in 7.0% of patients during the 2009 season,
with similar ﬁndings recorded in 2010 (Figure 1a; Supplementary
Table S1).
Treatment change following initial INS prescription also
commonly occurred for both SAR and NSUAD patients. For SAR
patients, GPs changed the INS (within class; 2009: 4.0%; 2010:
4.1%), added on to the initial INS monotherapy (2009: 21.3%; 2010:
24.6%), or changed INS and added on (2009: 2.8%; 2010; 2.8%;
Figure 1b; Supplementary Table S1). Again, treatment changes
following initial INS monotherapy prescription were more
apparent for NSUAD patients. Doctors either changed INS (2009;
8.2%; 2010: 7.0%), added on to the INS (2009; 43.6%; 2010; 41.4%)
or both (2009: 5.7%; 2010: 4.8%) (Figure 1b; Supplementary
Table S1).
For all patients who added on therapies,472% added a single
therapy, 424% added two and 42% added three, regardless of
whether they started on an OAH or an INS. For patients adding
therapies, those who initially received an OAH monotherapy
prescription were most commonly prescribed INS add-on
(2009: 56.5%; 2010: 55.0%). Those who initially received INS
monotherapy prescription were most commonly prescribed an
OAH add-on (2009; 77.1%; 2010; 77.6%). Eye drops were a more
common therapy add-on for patients who started the season on
OAH monotherapy (2009: 26.0%; 2010: 27.2%) than for patients
starting the season on INS monotherapy (2009: 10.6%; 2010: 9.5%;
Supplementary Table S1).
Dynamics of prescription change during the season
There was a shift to multiple therapy prescription during both
seasons for both SAR and NSUAD. The proportion of SAR patients
prescribed multiple therapy increased from 33% at season start to
45% at season end for both years (Table 3; Figure 1c). This shift
was even more apparent for NSUAD, where the proportion on
multiple therapy doubled from 23% at season start to 53.5% and
52.0% at season end for 2009 and 2010, respectively (Table 3;
Figure 1c). For these NSUAD patients, the proportion on dual
therapy doubled over the 2009 and 2010 seasons, from 19% at
start to ≈40% at end, and the number on triple therapy almost
tripled during both seasons, from 4% at start to 11.2% at end
(Table 3).
Table 1. Patient demographic and baseline characteristics
2009 (n= 25,069) 2010 (n=22,381)
SAR (n= 18,341) NSUAD (n= 6,728) SAR (n= 16,187) NSUAD (n= 6,194)
Age, years mean (s.d.) 31.3 (20.1) 46.5 (22.1) 32.1 (20.3) 47.7 (21.9)
Male, n (%) 8,811 (48.0) 2,636 (39.2) 7,679 (47.4) 2,426 (39.2)
Recorded smoking status, n (%) 15,406 (84.0) 6,397 (95.1) 13,266 (82.0) 5,873 (94.8)
Non-smokers 11,050 (71.7) 4,101 (64.1) 9,444 (71.2) 3,728 (63.5)
Current smokers 1,889 (12.3) 707 (11.1) 1,637 (12.3) 644 (11.0)
Ex-smokers 2,467 (16.0) 1,589 (24.8) 2,185 (16.5) 1,501 (25.5)
Asthma diagnosis, n (%) 7,145 (39.0) 3,745 (55.7) 5,517 (34.1) 3,270 (52.8)
Eczema diagnosis, n (%) 6,481 (35.3) 2,645 (39.3) 5,603 (34.6) 2,364 (38.2)
Urticaria, n (%) 1,621 (8.8) 809 (12.0) 1,553 (9.6) 596 (9.6)
Nasal polyps, n (%) 167 (0.9) 283 (4.2) 150 (0.9) 263 (4.2)
Abbreviations: NSUAD, nonseasonal upper airways disease; SAR, seasonal allergic rhinitis.
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Multiple therapy partners at season end
The most common multiple therapy regimen at season end was
OAH+INS for both SAR and NSUAD patients (Table 3). The
proportion prescribed this dual therapy was slightly higher for
NSUAD patients (2009: 21.5%; 2010: 20.6%) than for SAR patients
(2009: 16.0%; 2010: 16.0%). Adding eye drops to either OAH
monotherapy or OAH+INS dual therapy was the next most
common prescribing option in both groups for both seasons;
OAH+eye drops (SAR: ≈11%; NSUAD: ≈7%); OAH+INS+eye drops
(SAR: ≈11%; NSUAD: ≈7%) (Table 3).
General practice consultations
Many patients required an additional GP consultation after the
initial consultation of the season. Almost one-third of patients
(2009: 31.5%; 2010: 30.7%) who started the season on a
monotherapy had an additional GP consultation (Figure 2a). Most
of them incurred one additional visit (2009: 22.6%; 2010; 22.5%),
but some reconsulted twice (2009: 6.4%; 2010: 6.1%) or even three
times (2009: 1.8%; 2010: 1.3%). Patients who started the season on
dual therapy also frequently reconsulted their GP (2009: 16.9%;
2010: 15.7%). Similar ﬁgures were seen for those who commenced
the season on three and even four therapies (Figure 2a).
As the number of therapies prescribed during the season
increased, so did the number of GP consultations (Figure 2b). Of
patients who had received two therapies by the end of the season,
46.3% in 2009 and 45.5% in 2010 reconsulted their GP. The
number of reconsultations was similar for patients prescribed
three AR therapies over the season (2009: 44.1%; 2010: 42.2%).
Of patients who had received four AR therapies during the season,
85.0% in 2009 and 79.3% in 2010 reconsulted, with most revisiting
two (2009: 33.1%; 2010: 22.1%) and three times (2009: 30.0%;
2010: 23.6%).
DISCUSSION
Main ﬁndings
This study provides a comprehensive view of AR therapy failure
and co-prescribing behaviour among GPs in the UK during two
separate seasons and according to AR phenotype (i.e., SAR and
NSUAD). It provides data on how AR patients are treated in a
real-world setting, in terms of initial prescription(s), treatment
outcomes for patients with monotherapy failure, shifts to
co-prescribing practices, most common multi-therapy regimens
and the need for repeated GP consultations as a function of both
initial and overall prescriptions during the season.
The survey found that the majority of patients, both SAR and
NSUAD, received a monotherapy as their initial prescription of
the season, but that this monotherapy (whether OAH or INS)
proved to be insufﬁcient for many, necessitating additional GP
consultations to adjust treatment. NSUAD patients were more
likely to fail on monotherapy, with almost 50% returning to their
GP to either change the drug or to add an additional therapy.
Monotherapy with INS proved to be inadequate for about
25% of SAR sufferers, an unexpectedly high proportion given
their primacy of effect according to guidelines.1,29,30,33 More
than 15% of patients initially prescribed multiple therapies also
necessitated additional GP consultations for rhinitis-related
motives. This suggests that current rhinitis treatment, including
monotherapy and multiple therapies, does not meet patient
clinical needs.
Interpretation of ﬁndings in relation to previously published work
Such failure rates could be because AR is becoming more difﬁcult
to manage, with many patients presenting to their doctor with
moderate/severe and persistent disease,11,18 with mixed disease
(i.e., an allergic and non-allergic component)22 and with sensitivity
to multiple allergens (i.e., polysensitisation), some of which may be
inter-related.4,20,21 For many, INS monotherapy does not provide
the expected level of symptom relief,34 highlighting the need for a
more effective AR treatment option. Another possibility is that
patients were not shown how to use their nasal spray properly,33
nor were they told that it requires regular use over several days
before effects are noticed. One in ﬁve patients who receive
guideline-directed care remain symptomatic with signiﬁcant
impairment to their quality of life, a phenotype known as severe
chronic upper airway disease.23
Many SAR and NSUAD sufferers (33% and 23%, respectively)
received a multi-therapy regimen as their initial prescription. OAH
+INS was the most common co-prescription for both groups, but
eye drops were also frequently added to OAH, INS and OAH+INS
Table 2. Initial recorded prescription of the period 1st March-31st August
N (%) 2009 (n=25,069) 2010 (n=22,381)
SAR (n= 18,341) NSUAD (n=6,728) SAR (n= 16,187) NSUAD (n=6,194)
Monotherapy
OAH 9,505 (51.8) 3,378 (50.2) 8,495 (52.5) 3,108 (50.2)
INS 1,462 (8.0) 1,027 (15.3) 1,172 (7.2) 1,025 (16.6)
Systemic steroid 656 (3.6) 472 (7.0) 560 (3.5) 365 (5.9)
ED 559 (3.1) 251 (3.7) 472 (2.9) 219 (3.5)
Non-steroidal spray 68 (0.4) 35 (0.5) 40 (0.3) 35 (0.6)
LTRA 38 (0.2) 16 (0.2) 26 (0.2) 8 (0.1)
Immunotherapy 1 (0.01) 2 (0.03) 1 (0.01) 3 (0.1)
Total single therapy 12,289 (67.0) 5,181 (77.0) 10,766 (66.5) 4,763 (76.9)
Multiple therapy
OAH+INS 2,153 (11.7) 676 (10.1) 1,882 (11.6) 622 (10.0)
OAH+ED 1,636 (8.9) 240 (3.6) 1,472 (9.1) 229 (3.7)
OAH+INS+ED 1,635 (8.9) 204 (3.0) 1,543 (9.5) 180 (2.9)
INS+ED 330 (1.8) 97 (1.4) 287 (1.8) 84 (1.4)
OAH+LTRA 27 (0.2) 128 (1.9) 14 (0.1) 116 (1.9)
Other multiple therapy 271 (1.5) 202 (3.0) 223 (1.4) 200 (3.2)
Total multiple therapy 6,052 (33.0) 1,547 (23.0) 5,421 (33.5) 1,431 (23.1)
Abbreviations: ED, eye drops; INS, intranasal corticosteroid; LTRA, leukotriene receptor antagonists; OAH, oral antihistamine; NSUAD, nonseasonal upper
airways disease; SAR, seasonal allergic rhinitis.
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regimens. The high co-prescription rate at the start of both
seasons was a further unexpected ﬁnding, which implies that
these sufferers most likely were prescribed multiple therapies in
previous seasons and thus started subsequent seasons on the
same regimen. However, the high rate of additional consultations
for multiple therapy starters suggests that symptom control was
insufﬁcient for these patients as well. Furthermore, the prevalence
of eye drop addition to monotherapy and dual therapies
(particularly for SAR) emphasises the burden of ocular symptoms
for AR patients and the inadequacy of OAH and INS to effectively
control them, a ﬁnding supported by others.10,11
Strengths and limitations of this study
This large database survey included GP prescription data from 354
UK practices and information on 25,069 AR patients in 2009 and
22,381 in 2010. As it used the prescription data only, rather than
patient-reported outcomes, it provides a unique insight into the
burden of AR from the payer perspective. Over-the-counter
medication use was not captured in the OPCRD. As patients
frequently self-medicate, the true prevalence of multi-therapy use
is likely to be much higher than that reported here.35,36 Patients in
the database were ‘real-life’ patients, with a diagnosis of rhinitis
routinely recorded by their GP, and are representative of the AR
population as a whole in the UK. Assessment of data over two
complete and consecutive seasons, with similar ﬁndings recorded,
conﬁrms the robustness of the data. A period broader than the
pollen season deﬁned in the literature was chosen to ensure that
the ﬁrst prescription of the season was captured.37 Categorisation
of patients according to AR phenotype provided an insight into
how seasonal and nonseasonal patients are managed in a GP
setting. Higher co-prescribing behaviour and monotherapy failure
observed for nonseasonal patients demonstrates the sensitivity of
this database survey to quantify the burden of disease by AR
phenotype. Finally, one of the strengths of the study is its
observational nature, which allowed an overview of the current
state of practice in the UK. Although lacking in precision, this
approach provides insights into prescribing behaviour that could
hardly be obtained with other approaches, as even patient or
doctor surveys can act as an intervention, distorting behaviour.
A potential limitation of the survey was that no information was
recorded on the method of AR diagnosis, the type of contact
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Figure 1. Prescription outcome for patients who started the season on monotherapy, with either (a) oral antihistamine (OAH) or (b) intranasal
corticosteroid (INS) and (c) the proportion of seasonal allergic rhinitis (SAR) and nonseasonal upper airways disease (NSUAD) patients
prescribing multiple therapies at the start and end of the season, for the 2009 and 2010 seasons. 2009—SAR: n= 12,289; NSUAD: n= 5,181.
2010—SAR: n= 10,766; NSUAD: n= 4,764. For c: 2009—SAR: n= 18,341; NSUAD: n= 6,728; 2010—SAR: n= 16,187; NSUAD: n= 6,194.
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between GPs and patients when treatment was escalated or
changed, or on the rationale for prescribing choices, which would
have permitted a more precise assessment of concordance with
guideline-recommended diagnosis procedure.1,28 Patients were
also not categorised according to disease severity (i.e., mild and
moderate/severe), which may have yielded interesting sensitivity
ﬁndings. As AR patients frequently purchase medication over the
counter without seeking professional help, it is possible that our
sample was skewed towards more severe AR patients who
experience symptoms that are debilitating enough to visit their
GP.35,36 To capture the full population of patients with rhinitis, we
included all Read codes on rhinitis, hay fever and AR ever recorded
(Supplementary Table S2), as it was possible that these codes
could be present only once in a patient’s medical history. We then
used AR therapy prescriptions as a proxy for AR management.
However, there is a possibility that scripts for the drugs classiﬁed
as AR therapy were prescribed for another indication. Many
patients were diagnosed with co-morbid asthma or eczema, but
while asthma treatment may include systemic steroids, only a
small proportion of patients in the current study received such
prescriptions (4–7%). Furthermore, although eczema treatment
may include OAH, it is more commonly managed with topical
therapies.38 Finally, urticaria (which often does not require
treatment; http://www.nhs.uk/conditions/nettle-rash/Pages/Intro
duction.aspx) and nasal polyps may be treated with OAH and INS,
respectively, but the number of patients with these co-morbidities
was relatively low (9–12% and 1–4% for urticaria and nasal polyps,
respectively). Very few patients in this study received immunother-
apy. This treatment is typically prescribed by allergists/specialists in
the UK and thus captured infrequently in the database, thereby
precluding an assessment of its role in seasonal and nonseasonal
therapy. Although the data are speciﬁc to the UK, they do offer
important insight to other countries, and add to the overall evidence
of a high incidence of multiple therapy prescriptions, a trend that has
been observed in many European countries,39–42 as well as in the
United States.43
Implications for future research, policy and practice
A shift to increased multi-therapy prescription was noted for both
SAR and NSUAD patients, as the season progressed. As the
number of therapies prescribed increased, so did the number of
additional GP consultations. By season end, about 45% of SAR and
over half of NSUAD sufferers were prescribed multiple therapies,
not including over-the-counter medication usage. Although it is
possible that patients changed treatment because of drug
intolerance, the majority of patients received add-on therapy,
suggesting that intolerance was not a major issue. Furthermore,
to our knowledge, intolerance is not a major problem for
non-sedating antihistamines and intranasal steroids used to treat
AR. The in-season shift to multi-therapy use was most apparent in
Table 3. Dynamics of prescription changes during the hay fever season
N (%) 2009 (n=25,069) 2010 (n=22,381)
SAR (n=18,341) NSUAD (n= 6,728) SAR (n= 16,187) NSUAD (n=6,194)
Season start Season end Season start Season end Season start Season end Season start Season end
Monotherapy 12,289 (67.0) 10,136 (55.3) 5,181 (77.0) 3,130 (46.5) 10,776 (66.6) 8,850 (54.7) 4,764 (76.9) 2,974 (48.0)
Dual therapy 4,314 (23.5) 5,892 (32.1) 1,265 (18.8) 2,741 (40.7) 3,782 (23.4) 5,213 (32.2) 1,172 (18.9) 2,445 (39.5)
Triple therapy 1,717 (9.4) 2,243 (12.2) 272 (4.0) 755 (11.2) 1,615 (10.0) 2,062 (12.7) 244 (3.9) 694 (11.2)
4 therapies 20 (0.1) 68 (0.4) 10 (0.2) 92 (1.4) 24 (0.2) 62 (0.4) 14 (0.2) 77 (1.2)
5 therapies 1 (0.0) 2 (0.0) 0 (0.0) 9 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.1)
Total multiple therapies 6,052 (33.0) 8,205 (44.7) 1,547 (23.0) 3,598 (53.5) 5,421 (33.5) 7,337 (45.3) 1,430 (23.1) 3,220 (52.0)
Multiple therapies prescribed by season end
OAH+INS 2,938 (16.0) 1,448 (21.5) 2,590 (16.0) 1,278 (20.6)
OAH+INS+ED 2,026 (11.0) 466 (6.9) 1,894 (11.7) 453 (7.3)
OAH+ED 2,086 (11.4) 479 (7.1) 1,882 (11.6) 453 (7.3)
INS+ED 385 (2.1) 143 (2.1) 335 (2.1) 127 (2.1)
Other 770 (4.2) 1,062 (15.8) 636 (3.9) 909 (14.7)
Abbreviations: ED, eye drop; INS, intranasal corticosteroid; NSUAD, nonseasonal upper airways disease; OAH, oral antihistamine; SAR, seasonal allergic rhinitis.
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multiple GP consultations during the 2009 and 2010 seasons
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to 31 August for both years. 2009: n= 25,069; 2010: n= 22,381.
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NSUAD. Prescribing increasing numbers of therapies from
different AR medication classes would appear to be the logical
response to monotherapy failure, increasing pathologic coverage
and leading to improved symptom control. In the present survey,
the most common treatment regimens at the end of the season
was OAH+INS. However, this is neither recommended by the ARIA
guidelines because of insufﬁcient evidence,1 nor supported by
evidence from the literature.31,32 Furthermore, this study found no
evidence of improved outcomes in patients prescribed multi-
therapy classes, as indicated by the frequent need for additional
GP consultations in that group.
Our ﬁndings are consistent with the fact that the majority of
moderate/severe AR patients are on multiple therapies in real life
but continue to experience debilitating AR symptoms. Surveys
assessing both prescription and over-the-counter medication
use have shown co-medication behaviour in 66.0–74.4% of
sufferers.34,37,40,44 These patients are constantly looking for new
medications in an effort to ﬁnd something that ‘works’,45 a
treatment that can provide better and faster relief from both nasal
and ocular symptoms.37 Disappointingly, patients continue to
experience signiﬁcant nasal and ocular symptom breakthrough
despite treatment, even with multiple therapies,11,39,46 suggesting
that there is an unmet pharmacologic need in AR.
A subgroup analysis in patients with co-morbid asthma
(Supplementary Table S3) showed that SAR patients with an
asthma diagnosis were less likely to be prescribed multiple
therapies, both at the start and at the end of the season. This may
reﬂect beneﬁts of asthma treatment on rhinitis symptoms that
have been previously described,47,48 and deserves to be explored
in more detail in future studies.
Conclusions
This study is the largest body of evidence investigating clinician
prescribing behaviour in AR in the UK, and should be informative for
both payers and prescribers. The high rate of monotherapy failure,
the shift to multi-therapy prescription and the need for additional
consultations during the season are useful proxy measures to assess
unmet need. The extent of therapy failure and the rise in co-
prescriptions during both seasons demonstrates that current therapy
provides insufﬁcient symptom relief for many patients and will
increase the cost of AR management, both directly (drug costs) and
indirectly (additional GP visits, absenteeism and presenteeism). Taken
together, these ﬁndings support the need for novel AR treatment
options that provide faster and more complete symptom control
than current ﬁrst-line therapies. However, as the majority of patients
remained on their ﬁrst medication, it is also vital to identify those
who require more than one treatment at therapy initiation.
MATERIALS AND METHODS
Study design, study period and data collection
This was a prospective study of a historical cohort conducted with data
from the Optimum Patient Care Research Database (OPCRD).49 The OPCRD
is a quality-controlled, longitudinal, primary respiratory care database
containing anonymous data from 354 general practices across the UK.
The database contains information on patient management in primary and
secondary care and combines electronic patient records with linked
patient-reported data, which are collected using disease-speciﬁc
questionnaires. These routine clinical data are extracted from
practice management systems and include, for example, demographic
characteristics, co-morbidities and current therapy.
Routine consultation data from electronic patient records, recorded by
GPs at each patient visit, were used in this study. This included face-to-face
consultations, telephone consultations and home visits. Diagnoses and
prescription data were collected for both the 2009 and 2010 UK pollen
seasons in order to assess consistency of ﬁndings. The season was deﬁned
as 1st March to 31st August, coinciding with the months in both years
when most patients received an AR diagnosis or prescription.
The OPCRD has received approval for use in clinical research by the
Trent Multi-Centre Research Ethics Committee (approval reference
10/H0405/3). Formal ethics and research management approval for this
study were gained from the Anonymised Data Ethics Protocols and
Transparency committee, which is the independent scientiﬁc advisory
committee for the OPCRD.
OPCRD patients
N2009 = 721,056 
N2010 = 721,056 
Rhinitis-treated patients
N2009 = 134,870; N2010 = 127,043 
Registered at practice during
study period
N2009 = 113,727; N2010 = 104,287 
Hay-fever diagnosis
N2009 = 25,187; N2010 = 22,582 
No maintenance oral steroids
during baseline period
N2009 = 25,069; N2010 = 22,381 
Patients diagnosed with hay-fever and
treatment for rhinitis
N2009 = 25,069; N2010 = 22,381 
Exclusion criteria:
Did not receive rhinitis therapy
N2009 = 576,948; N2010 = 583,957
Only received LTRA during study period 
and had been receiving LTRA previously
N2009 = 21,143; N2010 = 19,125 
Exclusion criterion:
Not registered at practice during
baseline and outcome period
Exclusion criterion:
Never received a Read code for hay fever
N2009 = 88,540; N2010 = 75,318 
Exclusion criterion:
Received scripts for maintenance oral 
steroids in baseline period
N2009 = 118; N2010 = 131 
Inclusion criterion:
Received a script for SAR MAR-
AUG 2009/2010
Inclusion criteria:
Registered at practice for 6
months prior to start of
treatment and during hay fever
season and up till end of AUG
Inclusion criterion:
Hay fever diagnosis in clinical 
records
Figure 3. Consort Diagram. OPCRD, Optimum Patient Care Research Database. Patient data were taken from the OPCRD. Inclusion and
exclusion criteria were applied as described in the text.
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Patients
Included patients had a Read code-recorded diagnosis relating to hay fever
or rhinitis at any time in the OPCRD (Supplementary Table S2), and had
received at least one AR therapy prescription during the period from 1
March to 31 August 2009 and/or 2010. Recorded AR therapies included
OAH, INS, non-steroidal nasal sprays, leukotriene receptor antagonists,
topical ocular therapy for allergic conjunctivitis (eye drops) and systemic
treatments, including systemic corticosteroids and immunotherapy. Non-
steroidal nasal sprays included nasal antihistamines (24% of all prescrip-
tions in this category) decongestants (oxymetazoline, xylometazoline and
ephedrine), anticholinergics (ipratropium) and anti-inﬂammatory prepara-
tions (cromolyn and sodium cromoglicate). Furthermore, patients were
categorised as having either SAR or receiving prescriptions for NSUAD. The
latter proxy was designed to capture patients with perennial AR who
probably account for the majority of the NSUAD group. Patients deﬁned as
SAR patients had no recorded AR treatment in the six months preceding
the ﬁrst prescription of the study period (i.e., symptoms were purely
seasonal). Patients deﬁned as NSUAD patients suffered from symptoms
during the pollen season and outside it, as indicated by at least one AR
therapy prescription in the six months preceding the ﬁrst prescription of
the study period. Patients with NSUAD who did not also experience a
seasonal ﬂare, as indicated by no prescription during the season, were thus
excluded.
Patients receiving maintenance oral steroids during the six months
before the study period were excluded, as long-term oral steroids may
blunt SAR symptoms. Patients who received leukotriene receptor
antagonists alone during the preceding 6 months were also excluded, as
the leukotriene receptor antagonists may have been prescribed for the
treatment of asthma rather than AR (Figure 3).
Study end points
Socio-demographic information was collected, including patients’ age,
gender and smoking history. Co-morbid diagnoses of asthma, urticaria,
eczema and/or nasal polyps were also noted. Medication-related end
points for the period from 1st March to 31st August for both 2009 and
2010 included the following:
● First recorded prescription of the season (i.e., monotherapy or multiple
therapy).
● Treatment outcomes for patients who started the season on mono-
therapy. Outcomes were categorised into 4 groups: (i) stay on the same
therapy; (ii) change drug; (iii) add on a new therapy; and (iv) change
drug and add on a new therapy.
● Dynamics of prescription change during the season (i.e., proportion of
patients on monotherapy and multiple therapy at season start and
season end) and the proportion of each multiple therapy regimen by
season end.
● Proportion of patients requiring additional consultations for rhinitis (i.e.,
where a rhinitis-related Read code was recorded) after the ﬁrst
consultation of the hay fever season, according to number of therapies
prescribed at the beginning and during the season.
Statistics
Data were analysed using IBM SPSS Statistics for Windows, Version 21.0
(Released 2012; IBM Corp., Armonk, New York, NY, USA). Descriptive
statistics (mean, s.d.) were computed to summarise patient demographic
and baseline characteristics. All other data are presented as number of
patients and percentage of the population. Data are presented by AR
phenotype (i.e., SAR or NSUAD) and by year (i.e., 2009 and 2010).
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